With ma­jor back­ing from New York and Chi­na, Athenex sets sights on a $100M can­cer drug IPO

John­son Lau wants to make his come­back as CEO of a pub­lic biotech com­pa­ny, even though the last out­ing 15 years ago didn’t go so well.

Lau and his crew have set their sights on a $100 mil­lion wind­fall for Athenex, a Buf­fa­lo-based can­cer drug de­vel­op­er which has made a com­mit­ment to hire hun­dreds of staffers to win a $200 mil­lion com­mit­ment from the state to fund the con­struc­tion of a new man­u­fac­tur­ing com­plex.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER